1–9 of 9 results for Treatment burden
Three-Year Outcomes of the PALADIN Phase IV Study: Comparison of Anatomical Metrics, Efficacy, and Treatment Burden Post FAc
Christopher D. Riemann, MD
Annual Meeting Talks
2022
The Role of Subretinal Surgery in the Treatment of Resistant Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
Nabil M. Jabbour, MD, FACS
On Demand Cases, Courses, and Papers
2021
Episcleral Brachytherapy for Exudative Macular Degeneration
Gregg T. Kokame, MD, MMM, FASRS
2020
Number of Injections and Time to Dry Analysis of Brolucizumab Versus Aflibercept in Patients With Neovascular AMD: 96-Week Data From HAWK and HARRIER
Carl D. Regillo, MD
High-dose Aflibercept Therapy in nAMD and DME Eyes With Suboptimal Response to Standard Dose of Anti-VEGF Therapy: A Retrospective Analysis
Jared S. Nielsen, MD, MBA
Treatment Burden and Vision Analysis of Anti-VEGF Therapies for the Treatment of Neovascular AMD
Rahul Komati, MD
Abicipar for nAMD Provides Faster Retinal Fluid Resolution, and Achieved Similar Dryness Through Week 104 With Fewer Injections
Nancy M. Holekamp, MD, FASRS
Effect on Treatment Burden Post - Versus Pre-Iluvien Based on Prior DME Treatments
Caesar K. Luo, MD, FASRS
2018
2 Real-World Analyses of Treatment Burden Associated With Intravitreal Injections for DME Prior to 0.2 mcg/Day Fluocinolone Acetonide (FAc)